Scientists Engineer Insulin-Producing Cells That Hide From the Immune System

Researchers have developed a new type of insulin-secreting organoid grown from gastric tissue that naturally resists immune attack and can be further engineered to evade destruction. This advance could make cell transplants for Type 1 diabetes more viable.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsimmunotherapyadvancements

Key takeaways

Gastric insulin-secreting organoids (GINS) produce insulin in response to blood sugar and naturally express fewer of the proteins that trigger Type 1 diabetes autoimmunity
When engineered to produce PD-L1, a molecule that suppresses immune attacks, GINS survived significantly longer when exposed to T cells that normally destroy insulin-producing cells
This work is still in early laboratory stages and has not yet been tested in people
The approach could potentially benefit both transplants between different people and transplants using a person's own engineered cells

A New Source of Insulin-Producing Cells

One major challenge in Type 1 diabetes cell therapy is finding or creating insulin-producing cells that can survive inside the body without being attacked by the immune system. Researchers have now turned to an unexpected source: the stomach.

Scientists grew insulin-secreting organoids—tiny, three-dimensional structures—from gastric (stomach) stem cells. When compared in the laboratory to insulin-producing cells derived from induced pluripotent stem cells (iPSC-islets), the gastric organoids responded normally to changes in blood sugar and produced insulin appropriately.

Natural Protection Against Immune Attack

A key finding was that these gastric organoids naturally expressed lower levels of proteins that typically trigger Type 1 diabetes autoimmunity. This built-in feature made them inherently more resistant to attack by the immune system compared to other cell sources tested in the same study.

To test this resistance, researchers exposed the organoids to engineered T cells (called Avatar Teffs) designed to mimic the immune attack seen in Type 1 diabetes. The gastric organoids survived this attack better than control cells, suggesting they have intrinsic protection mechanisms.

Engineering Additional Immune Shields

To strengthen protection further, the research team modified the gastric stem cells to produce PD-L1, a molecule known to suppress immune responses. This modification did not interfere with the cells' ability to produce insulin and respond to blood sugar.

When exposed to immune T cells in laboratory conditions mimicking the body's environment, the PD-L1-engineered organoids attracted fewer T cells and maintained significantly higher viability than untreated organoids. This protection worked even when the immune cells came from the same person the organoids were grown for—a critical test for autologous (self-derived) transplantation.

What This Means for Future Therapy

This research identifies gastric insulin-secreting organoids as a promising platform for Type 1 diabetes cell replacement therapy. The combination of natural immune-evading features and engineered protection through PD-L1 could make transplanted cells more likely to survive and function long-term.

The findings support the potential use of these cells for both allogeneic transplants (cells from a donor) and autologous transplants (a person's own engineered cells). However, this work remains in early laboratory stages. Much additional research in animal models and eventually clinical trials would be needed before this approach could be used to treat patients.

Evidence label

Source: bioRxiv : the preprint server for biology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.